CA
NZ
UK
AU
IND
US
…
Stemsation International, Inc. researches, develops, manufactures, and sells canned and flavored oxygen products in the United States. The company sells its products through business to business and direct to consumers channels. Stemsation International, Inc. was incorporated in 2006 and is headquartered in Plantation, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Stemsation International Inc (ticker STSN) is limited and filings provide few operational details, so the company's core activities and product lines are not well documented. Because key disclosures are sparse, long-term growth drivers cannot be reliably identified; investors seeking microcap exposure may view potential upside but should be cautious given the information shortfall.
Key investment risks include thin trading liquidity and high volatility typical of PINK-listed microcaps, possible absence of audited financial statements and robust corporate governance, and heightened risk of dilutive financings or regulatory delisting.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.46M | -0.90M | -0.09M | -0.30M | -0.34M |
| Net income | -0.46M | -0.90M | -0.09M | -0.44M | -1.15M |
| Ebit | - | - | -0.06M | -0.29M | -0.17M |
| Ebitda | -0.39M | -0.85M | 0.11M | -0.06M | 0.06M |
| Depreciation and amortization | - | - | 0.17M | 0.23M | 0.24M |
| Operating income | -0.39M | -0.85M | -0.07M | -0.06M | -0.17M |
| Other operating expenses | 0.39M | 0.85M | 0.08M | 0.06M | 0.17M |
| Interest expense | 0.07M | 0.05M | 0.02M | 0.24M | 0.17M |
| Income tax expense | - | - | -0.17M | 0.14M | 0.81M |
| Total operating expenses | 0.39M | 0.85M | 0.08M | 0.06M | 0.17M |
| Total other income expense net | -0.07M | -0.05M | -0.00M | -0.24M | -0.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 12.99M | 12.99M | 0.04M | 0.06M | 0.08M |
| Other current assets | 0.38M | 0.38M | 0.04M | 0.05M | 0.07M |
| Total liab | 1.99M | 1.53M | 0.73M | 0.91M | 0.98M |
| Total stockholder equity | 10.99M | 11.46M | -0.68M | -0.85M | -0.90M |
| Other current liab | 0.49M | 0.36M | 0.36M | 0.36M | 0.63M |
| Common stock | 0.06M | 0.06M | 0.03M | 0.02M | 0.02M |
| Retained earnings | -6.60M | -6.14M | -5.24M | -5.15M | -4.71M |
| Cash | 0.00M | 0.00M | 0.00M | 0.01M | 0.01M |
| Total current liabilities | 1.99M | 1.53M | 0.73M | 0.91M | 0.91M |
| Net debt | 1.50M | 1.08M | 0.28M | 0.45M | 0.21M |
| Short term debt | 1.50M | 1.09M | 0.28M | 0.46M | 0.21M |
| Short long term debt total | 1.50M | 1.09M | 0.28M | 0.46M | 0.21M |
| Other stockholder equity | 17.52M | 17.52M | 4.52M | 4.27M | 3.79M |
| Total current assets | 0.39M | 0.39M | 0.04M | 0.06M | 0.08M |
| Net receivables | - | - | - | - | 0.00M |
| Accounts payable | - | 0.09M | 0.08M | 0.09M | 0.07M |
| Accumulated other comprehensive income | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Non current assets total | 12.60M | 12.60M | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | - | -0.34M | - | - | - |
| Total cash from financing activities | 0.35M | 0.80M | 0.04M | 0.07M | 0.16M |
| Net income | -0.46M | -0.90M | -0.09M | -0.30M | -1.15M |
| Change in cash | -0.00M | 0.00M | -0.01M | -0.00M | -0.60M |
| Begin period cash flow | 0.00M | 0.00M | 0.01M | 0.01M | 0.02M |
| End period cash flow | 0.00M | 0.00M | 0.00M | 0.01M | -0.58M |
| Total cash from operating activities | -0.36M | -0.45M | -0.05M | -0.07M | -0.77M |
| Other cashflows from investing activities | - | -0.34M | -0.00M | - | - |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | - | - | 0.00M | -0.00M |
| Other cashflows from financing activities | - | - | 0.00M | 0.00M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.03M | 0.00M | -0.00M | 0.13M | 0.25M |
| Other non cash items | 0.07M | 0.44M | 0.04M | 0.10M | 0.14M |
| Free cash flow | -0.36M | -0.45M | -0.05M | -0.07M | -0.77M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| STSN Stemsation International Inc |
- -% |
0.01 | - | - | 727.92 | - | 2056.99 | -26.47 |
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Stemsation International, Inc. researches, develops, manufactures, and sells canned and flavored oxygen products in the United States. The company sells its products through business to business and direct to consumers channels. Stemsation International, Inc. was incorporated in 2006 and is headquartered in Plantation, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Ray C. Carter Jr. | Founder, CEO & Pres | NA |
| Dr. Mira Gadzala Ph.D. | Chief Science Officer | NA |
| Ms. Svetlana Nedkovska | Managing Director of Europe | NA |
| Mr. Nicholas B. Panza | Sec. | NA |
| Mr. Ray C. Carter Jr. | Founder, CEO & President | NA |
| Mr. Nicholas B. Panza | Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.39%
Communication Services
-0.43%
Consumer Cyclical
-0.47%
Consumer Defensive
-0.01%
Energy
+0.05%
Financial Services
-0.37%
Financials
-0.15%
Healthcare
-1.18%
Industrials
-0.47%
Real Estate
-0.28%
Technology
-1.06%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...